MDXH

MDxHealth SA (NASDAQ:MDXH) is a Belgian-based commercial-stage precision diagnostics company that specializes in urologic testing solutions. Founded in 2003 and originally known as OncoMethylome Sciences SA, the company changed its name to MDxHealth SA in 2010 and went public on NASDAQ in November 2021. Headquartered in Herstal, Belgium, MDxHealth has established itself as a focused player in the prostate cancer diagnostics market, offering a comprehensive menu of genomic and epigenetic tests that help physicians make more informed decisions about patient care while reducing the need for invasive procedures.